A detailed history of Cetera Investment Advisers transactions in United Therapeutics Corp stock. As of the latest transaction made, Cetera Investment Advisers holds 8,252 shares of UTHR stock, worth $3.03 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
8,252
Previous 6,167 33.81%
Holding current value
$3.03 Million
Previous $1.96 Million 50.56%
% of portfolio
0.01%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$311.04 - $363.55 $648,518 - $758,001
2,085 Added 33.81%
8,252 $2.96 Million
Q2 2024

Aug 22, 2024

BUY
$228.26 - $319.04 $112,532 - $157,286
493 Added 8.69%
6,167 $1.96 Million
Q1 2024

May 24, 2024

BUY
$210.76 - $249.51 $868,752 - $1.03 Million
4,122 Added 265.59%
5,674 $1.3 Million
Q1 2024

May 14, 2024

SELL
$210.76 - $249.51 $233,311 - $276,207
-1,107 Reduced 41.63%
1,552 $356,000
Q4 2023

Feb 13, 2024

BUY
$214.88 - $256.94 $42,331 - $50,617
197 Added 8.0%
2,659 $584,000
Q3 2023

Nov 14, 2023

BUY
$211.82 - $248.24 $44,482 - $52,130
210 Added 9.33%
2,462 $556,000
Q2 2023

Aug 09, 2023

BUY
$205.19 - $232.99 $60,531 - $68,732
295 Added 15.07%
2,252 $497,000
Q1 2023

May 15, 2023

BUY
$212.99 - $276.17 $1,277 - $1,657
6 Added 0.31%
1,957 $438,000
Q4 2022

Feb 14, 2023

BUY
$205.95 - $280.43 $163,112 - $222,100
792 Added 68.33%
1,951 $542,000
Q3 2022

Nov 10, 2022

BUY
$203.3 - $244.17 $41,269 - $49,566
203 Added 21.23%
1,159 $243,000
Q2 2022

Aug 11, 2022

BUY
$174.81 - $241.14 $167,118 - $230,529
956 New
956 $225,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.7B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.